applied cotreatment of nivolumab (anti‐PD‐1 therapy) and ipilimumab (anti‐CTLA‐4 therapy) in patients with melanoma and found an encouraging curative effect, ascribing to synchronous enhanced priming, activation and killing of CTLs.[39] More than combining with other type of ICB, chemotherapy plus immunotherapy is s alternative therapy option. This evidence concerns the gene CTLA4 and melanoma.